Recent advances in understanding the biochemical and molecular mechanism of diabetic retinopathy

Biomedicine and Pharmacotherapy

Volumn 74, Issue , 2015, Pages 145-147

  Wan, Ting Ting ^a   Li, Xiu Fen ^a   Sun, Yan Ming ^b   Li, Yan Bo ^a   Su, Ying ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Advanced glycation end products; Diabetic retinopathy; Hyperglycemia; Oxidative stress; Protein kinase C

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLUCOSE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE;

BIOCHEMISTRY; DIABETIC RETINOPATHY; ENZYME ACTIVATION; HUMAN; HYPERGLYCEMIA; MOLECULAR PATHOLOGY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; ADULT; ANIMAL; COMPLICATION; METABOLISM;

ADULT; ANIMALS; DIABETIC RETINOPATHY; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; OXIDATIVE STRESS; PROTEIN KINASE C;

EID: 84940875935     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2015.08.002     Document Type: Review

References (32)

1. Simo R., Hernandez C. Prevention and treatment of diabetic retinopathy: evidence from large, randomized trials. The emerging role of fenofibrate. Rev. Recent Clin. Trials 2012, 7:71-80.
2. Milne R., Brownstein S. Advanced glycation end products and diabetic retinopathy. Amino Acids 2013, 44:1397-1407.
3. Gurel Z., Zaro B.W., Pratt M.R., Sheibani N. Identification of O-GlcNAc modification targets in mouse retinal pericytes: implication of p53 in pathogenesis of diabetic retinopathy. PLoS One 2014, 9:e95561.
4. Singh L.P. Thioredoxin interacting protein (TXNIP) and pathogenesis of diabetic retinopathy. J. Clin. Exp. Ophthalmol. 2013, 4:1-29.
5. Kim D.I., Park M.J., Lim S.K., Choi J.H., Kim J.C., Han H.J., Kundu T.K., Park J.I., Yoon K.C., Park S.W., Park J.S., Heo Y.R., Park S.H. High-glucose-induced CARM1 expression regulates apoptosis of human retinal pigment epithelial cells via histone 3 arginine 17 dimethylation: role in diabetic retinopathy. Arch. Biochem. Biophys. 2014, 560:36-43.
6. Zhang L., Xia H., Han Q., Chen B. Effects of antioxidant gene therapy on the development of diabetic retinopathy and the metabolic memory phenomenon. Graefes Arch. Clin. Exp. Ophthalmol. 2015, 253:249-259.
7. Milne R., Brownstein S. Advanced glycation end products and diabetic retinopathy. Amino Acids 2013, 44:1397-1407.
8. Sharma Y., Saxena S., Mishra A., Saxena A., Natu S.M. Advanced glycation end products and diabetic retinopathy. J. Ocul. Biol. Dis. Inform. 2012, 5:63-69.
9. Zong H., Ward M., Stitt A.W. AGEs, RAGE, and diabetic retinopathy. Curr. Diab. Rep. 2011, 11:244-252.
10. Morigi M., Angioletti S., Imberti B., Donadelli R., Micheletti G., Figliuzzi M., Remuzzi A., Zoja C., Remuzzi G. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-κB-dependent fashion. J. Clin. Invest. 1998, 101:1905-1915.
11. Yamagishi S., Maeda S., Matsui T., Ueda S., Fukami K., Okuda S. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochim. Biophys. Acta 2012, 1820:663-671.
12. Inoguchi T., Li P., Umeda F., Yu H.Y., Kakimoto M., Imamura M., Aoki T., Etoh T., Hashimoto T., Naruse M., Sano H., Utsumi H., Nawata H. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000, 49:1939-1945.
13. Kuboki K., Jiang Z.Y., Takahara N., Ha S.W., Igarashi M., Yamauchi T., Feener E.P., Herbert T.P., Rhodes C.J., King G.L. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 2000, 101:676-681.
14. Pathak D., Gupta A., Kamble B., Kuppusamy G., Suresh B. Oral targeting of protein kinase C receptor: promising route for diabetic retinopathy?. Curr. Drug Deliv. 2012, 9:405-413.
15. Ganz M.B., Seftel A. Glucose-induced changes in protein kinase C and nitric oxide are prevented by vitamin E. Am. J. Physiol. Endocrinol. Metab. 2000, 278:E146-E152.
16. Yung S., Chau M.K.M., Zhang Q., Zhang C.Z., Chan T.M. Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocin-induced type I diabetic nephropathy. PLoS One 2013, 8:e54501.
17. Ha H., Mi R.Y., Yoon J.C., Kitamura M., Hi B.L. Role of high glucose-induced nuclear factor-κB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J. Am. Soc. Nephrol. 2002, 13:894-902.
18. Ushio-Fukai M. Redox signaling in angiogenesis: role of NADPH oxidase. Cardiovasc. Res. 2006, 71:226-235.
19. Cave A.C., Brewer A.C., Narayanapanicker A., Ray R., Grieve D.J., Walker S., Shah A.M. NADPH oxidases in cardiovascular health and disease. Antioxid. Redox Signal. 2006, 8:691-728.
20. Du Y., Veenstra A., Palczewski K., Kern T.S. Photoreceptor cells are major contributors to diabetes-induced oxidative stress and local inflammation in the retina. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:16586-16591.
21. Ungvari Z., Kaley G., de Cabo R., Sonntag W.E., Csiszar A. Mechanisms of vascular aging: new perspectives. J. Gerontol. A Biol. Sci. Med. Sci. 2010, 65:1028-1041.
22. Wu Y. Oxidative stress: implications for the development of diabetic retinopathy and antioxidant therapeutic perspectives. Oxid. Med. Cell. Longev. 2014, 2014:752387.
23. Kastelan S., Tomic M., Gverovic Antunica A., Salopek Rabatic J., Ljubic S. Inflammation and pharmacological treatment in diabetic retinopathy. Mediators Inflamm. 2013, 2013:213130.
24. King G.L. The role of inflammatory cytokines in diabetes and its complications. J. Periodontol. 2008, 79:1527-1534.
25. Gong Y., Fan Y., Liu L., Wu D., Chang Z., Wang Z. Erianin induces a JNK/SAPK-dependent metabolic inhibition in human umbilical vein endothelial cells. In Vivo 2004, 18:223-228.
26. Mocan M.C., Kadayifcilar S., Eldem B. Elevated intravitreal interleukin-6 levels in patients with proliferative diabetic retinopathy. Can. J. Ophthalmol. 2006, 41:747-752.
27. Li S., Fu X.A., Zhou X.F., Chen Y.Y., Chen W.Q. Angiogenesis-related cytokines in serum of proliferative diabetic retinopathy patients before and after vitrectomy. Int. J. Ophthalmol. 2012, 5:726-730.
28. Leal E.C., Martins J., Voabil P., Liberal J., Chiavaroli C., Bauer J., Cunha-Vaz J., Ambrosio A.F. Calcium dobesilate inhibits the alterations in tight junction proteins and leukocyte adhesion to retinal endothelial cells induced by diabetes. Diabetes 2010, 59:2637-2645.
29. Sabatino L., Casamassimi A., Peluso G., Barone M.V., Capaccio D., Migliore C., Bonelli P., Pedicini A., Febbraro A., Ciccodicola A., Colantuoni V. A novel peroxisome proliferator-activated receptor gamma isoform with dominant negative activity generated by alternative splicing. J. Biol. Chem. 2005, 280:26517-26525.
30. Knouff C., Auwerx J. Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr. Rev. 2004, 25:899-918.
31. Malecki M.T., Cyganek K., Mirkiewicz-Sieradzka B., Wolkow P.P., Wanic K., Skupien J., Solnica B., Sieradzki J. Alanine variant of the Pro12Ala polymorphism of the PPARgamma gene might be associated with decreased risk of diabetic retinopathy in type 2 diabetes. Diabetes Res. Clin. Pract. 2008, 80:139-145.
32. Costa V., Ciccodicola A. Is PPARG the key gene in diabetic retinopathy?. Br. J. Pharmacol. 2012, 165:1-3.